Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

Last updated: October 10, 2024
Sponsor: UNC Lineberger Comprehensive Cancer Center
Overall Status: Active - Recruiting

Phase

2

Condition

Hiv Infections

Hiv

Cervical Dysplasia

Treatment

Placebo vaginal inserts

Artesunate vaginal inserts

Clinical Study ID

NCT06519994
LCCC2330
R34CA284983
  • Ages > 25
  • Female

Study Summary

The objective of this randomized, placebo-controlled trial is to evaluate whether intravaginal artesunate pessaries (vaginal inserts) can be used as adjuvant therapy following thermal ablation to improve Human papillomavirus (HPV) treatment outcomes in Women Living with Human Immunodeficiency Virus (WLWH).

The study will evaluate whether women who use artesunate will have higher HPV clearance at 6 months, compared to those who used a placebo. The study will also assess the safety, adherence, and acceptability of this treatment. 120 participants will be enrolled in the study. Participants will self-administer the study drug nightly for 5 days, take a week off, and repeat twice (use study drug on weeks 1, 3,5) and will return to the clinic on weeks 2, 4, 6, 12, and week 24 for follow-up.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Age 25 years or older

  • Known HIV seropositive status

  • On antiretroviral therapy for > 90 days prior to enrollment

  • Weight ≥50 Kg at study entry*

  • Positive HPV screening test and within 4-8 weeks of thermal ablation

  • Ability to provide informed consent

  • Planning to stay within the study locale during the duration of the study (24 weeks)

  • Agreement to use contraception (barriers or hormonal) if of childbearing age through week 6 of the study

Exclusion Criteria

  • Current pregnancy or breastfeeding status

  • Current or past history of invasive cervical cancer

  • History of total hysterectomy

  • Currently receiving systemic chemotherapy or radiation therapy for another cancer

  • Current use of systemic immunosuppressants or steroids (>10 mg of prednisone or equivalent)

  • Current use of efavirenz antiretroviral therapy, phenytoin, carbamazepine, and rifampin

  • Have medical comorbidity that, in the opinion of the investigator, would interfere with study participation

  • Prior chemotherapy within 30 days prior to day 1 of study treatment

  • Male at birth

Study Design

Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Placebo vaginal inserts
Phase: 2
Study Start date:
July 04, 2024
Estimated Completion Date:
November 30, 2025

Study Description

WLWH face up to six times increased risk of cervical cancer, as a result, cervical cancer is a leading cause of death in this population. Cervical cancer is caused by persistent infection with the human papillomavirus (HPV), resulting in precancerous changes that if not adequately treated, progress to cancer. Thermal ablation is a commonly used treatment for cervical precancer in Kenya and other low- and middle-income countries (LMICs). Current treatments for HPV or cervical precancer, including thermal ablation, are associated with high rates of treatment failure in WLWH. In a recent study from Zambia, only 44% of WLWH had cleared HPV at six months following thermal ablation treatment. Other studies have demonstrated up to 30% recurrence rate of high-grade cervical precancer at 12 to 24 months after treatment. Persistent infection with HPV following precancer treatment is a key risk factor for treatment disease recurrence.

Connect with a study center

  • Lumumba Sub-County Hospital KEMRI- Research Care Training Program (RCTP) Building

    Kisumu, 614-40100
    Kenya

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.